Norwegian health authorities have blocked access to a potentially life-saving cancer treatment for patients with specific lymphoma types, sparking outrage among patients and medical professionals. The Decision Forum for New Methods, which evaluates medical treatments for Norway's public healthcare system, rejected CAR-T therapy for follicular lymphoma patients this week.
Andreas van Tunen, a 58-year-old from Treungen in Southern Telemark, has battled cancer for six years. He expressed shock at the decision. "I think it's a great shame. I find it incredible that people sitting in a forum can decide with a stroke of a pen whether you or I or anyone else can get vital treatment in this country," van Tunen said.
CAR-T represents some of the newest and most advanced developments in cancer treatment. The therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells. While Norway has approved CAR-T for two types of aggressive lymphoma and one blood cancer type, the recent rejection affects patients with slow-developing follicular lymphoma.
Follicular lymphoma is Norway's second most common lymphoma type, affecting approximately 250 people annually. The rejected application specifically concerned using a CAR-T variant as fourth-line treatment for patients who have experienced disease recurrence after at least three rounds of standard treatment.
Kari Sandberg, chair of the Lymphoma Association, expressed deep disappointment with the decision. "I'm desperate thinking about the patients this affects. These are real people who need vital treatment," she said. Sandberg noted that patients with this lymphoma form often live with the disease for many years, undergoing treatment after treatment with constant relapses.
The situation creates a two-tier healthcare system where wealthier patients can seek treatment abroad. "Some have health insurance, some have their own funds, and some get help through fundraising. But we cannot have it this way. A person standing alone without support gets no treatment. It's undignified," Sandberg stated.
Medical experts point to troubling disparities in treatment access. Doctor Marianne Brodtkorb from Oslo's Radium Hospital, who oversees van Tunen's treatment, noted the unfairness. "It's unjust that patients who are thoroughly treated for follicular lymphoma in Norway don't get this opportunity here, especially when they have few other alternatives."
The price negotiation appears central to the rejection. The Decision Forum specifically cited that "no price was offered that stands in reasonable proportion to documented clinical benefit" in their November decision. This comes despite CAR-T already being approved for another lymphoma type at an agreed price.
Doctor Alexander FossĂĄ, senior consultant at the Lymphoma Section of Oslo University Hospital, called the rejection unfortunate. "CAR-T is already established for other lymphoma types, and we know the treatment well. If it had been approved for follicular lymphoma, it could have been offered to patients who have been through three other treatment lines and have few good alternatives left."
Van Tunen's case highlights the human cost of these decisions. After three relapses since his 2018 diagnosis and suffering significant side effects from previous treatments, he now faces extensive travel to Sweden for treatment. "We live in Treungen in Southern Telemark, almost 45 minutes from Kristiansand airport, then flight to Oslo and onward to Arlanda. But it's worth it," he said.
The Norwegian healthcare system's cautious approach to new treatments creates longer waiting times compared to neighboring countries. Sandberg noted that Norway takes three to four times longer than Denmark to offer cancer patients new and innovative treatments. This delay forces patients to seek options abroad or go without potentially life-extending care.
The case raises fundamental questions about healthcare prioritization in Norway's universal system. While cost-effectiveness calculations are necessary, patients and doctors question whether the current evaluation methods adequately capture the value of treatments for chronic conditions like follicular lymphoma that develop over decades rather than years.